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ummary  The  last  century  has  witnessed  the  emergence  of  several  previously
nknown  viruses  as  life-threatening  human  pathogens.  Several  examples  include
IV,  Ebola,  Lujo,  and,  most  recently,  the  Middle  East  respiratory  syndrome  (MERS)
nd  Ebola.  In  this  study,  we  describe  a  method  for  the  swift  generation  of  a  human-
erived  monoclonal  antibody,  known  as  LCA60,  as  a treatment  for  MERS  infections.
CA60  antibody  was  generated  using  the  Cellclone  Technology  from  the  immor-
alized  B  cells  of  a  human  donor  recovering  from  MERS.  Only  four  months  were
equired  from  the  initial  screening  of  B  cells  to  the  development  of  a  stable  CHO
ell  line  suitable  for  the  production  of  clinical  grade  antibody,  thereby  delineat-
ng  a  rapid  pathway  for  the  development  of  antiviral  therapies  against  emerging
iruses.  Currently,  the  LCA60  antibody  is  being  considered  for  clinical  development,
hich  includes  prophylaxis  in  individuals  at  risk  and  a  treatment  for  severe  MERS-CoV
nfections.
 2016  King  Saud  Bin  Abdulaziz  University  for  Health  Sciences.  Published  by  Elsevier
imited.  All  rights  reserved.∗ Corresponding author.
E-mail address: davide.corti@humabs.ch (D. Corti).
ttp://dx.doi.org/10.1016/j.jiph.2016.04.003
876-0341/© 2016 King Saud Bin Abdulaziz University for Health Sciences. Published by Elsevier Limited. All rights reserved.
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MERS  is  a  highly  lethal  pulmonary  infection  [1]
caused  by  a  previously  unidentiﬁed  coronavirus
(CoV), which  is  thought  to  infect  Dromedary  camels
[2].  MERS  ﬁrst  surfaced  in  April  2012,  when  the  virus
was rapidly  identiﬁed  by  two  independent  groups.
MERS also  belongs  to  a  novel  subgroup  of  the  C  beta-
coronavirus  [3,4]  (Fig.  1).  MERS-CoV  spread  to  26
countries,  causing  episodes  of  infection  over  the
last three  years.  As  of  April  14,  2016,  a  total  of
1741 cases  and  675  deaths  were  reported  to  WHO,
of which  were  mostly  from  Saudi  Arabia.  Most  cases
of human  infection  are  not  transmitted  by  direct
contacts  with  camels  but  can  occur  through  direct
contact  with  MERS  patients  in  hospitals  [5]. Indeed,
healthcare  exposure  seems  to  play  a  key  role  in  the
spread of  MERS-CoV  outbreaks.
Treating  viruses  is  still  a  challenge  in  modern
medicine. The  most  effective  measure  to  com-
bat viral  diseases  is  preventive  vaccines.  However,
as observed  with  the  latest  Ebola  outbreak,  vac-
cines cannot  be  developed  and  applied  sufﬁciently
rapidly to  contain  acute  outbreaks.  Given  the  dan-
ger of  newly  emerging  viruses,  novel  strategies
need to  be  developed  to  generate  rapidly  effective
treatments. Interestingly,  antibody-based  treat-
ments are  one  of  the  most  promising  approaches
for the  treatment  and  prevention  of  viral  dis-
eases. Emil  V.  Behring  and  Kitasato  Shibasaburo¯
pioneered the  use  of  a  passive  antibody  ther-
apy in  the  early  1890s,  when  they  showed  that
hyperimmune sera  of  animal  origin  could  protect
against  diphtheria  and  tetanus.  Serum  therapy  for
other infections  followed  and  was  substituted  only
when antibiotics  were  discovered  in  the  1940s.
Unfortunately, the  use  of  polyclonal  animal  sera
is associated  with  several  side  effects,  including
hypersensitivity  reactions  and  serum  sickness,  that
Figure  1  Colored  transmission  electron  micrograph  of
MERS  coronavirus  particles  (orange)  budding  from  a  host
cell  (blue).
Credit:  Public  Health  England/Science  Photo  Library.
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esults  from  the  administration  of  large  amounts  of
nimal proteins.  These  problems  led  to  the  replace-
ent  of  animal  sera  with  human  hyperimmune
mmunoglobulin  preparations,  such  as  those  used  to
revent or  treat  or prevent  cytomegalovirus,  vari-
ella zoster  virus,  hepatitis  B  virus  and  respiratory
yncytial virus  (RSV)  infections  in  high  risk  popu-
ations.  Importantly,  Respigam,  the  hyperimmune
mmunoglobulin  product  against  RSV,  was  replaced
n 1998  by  Synagis,  the  ﬁrst  monoclonal  antiviral
ntibody  on  the  market.  Clinical  studies  showed
hat in  patients  with  severe  pneumonia  caused  by
iral infections,  the  convalescent  sera  conferred  a
herapeutic beneﬁt  when  administered  to  patients
ith severe  infections  during  the  Spanish  inﬂuenza,
neumonia from  1918  to  1919,  SARS-CoV  in  2003,
5N1 inﬂuenza  A  in  2006,  H1N1  inﬂuenza  A  virus
n 2009  and,  most  recently,  during  the  Ebola  out-
reak [6]. There  have  been  attempts  to  collect
herapeutic antibodies  from  the  serum  of  recover-
ng MERS  patients  as  well  as  people  living  with  these
atients  or  health  worker  contacts.  However,  it  was
ecently discovered  that  antibody  titers  in  conva-
escent plasma  are  too  low  to  produce  a  therapeutic
ffect (communication  from  Dr.  Yaseen  Arabi  during
he MERS-CoV  Research  Initiative  Workshop  held  on
—10 September  2015  in  Riyadh).
Thus, monoclonal  antibodies  are  an  ideal  alter-
ative to  hyperimmune  sera  or  hyperimmune
mmunoglobulin  preparations.  They  can  be  pro-
uced by  immortalizing  memory  B  cells  with
pstein—Barr virus  (EBV)  or  by  fusing  a  B  cell  with
n appropriate  partner  cell  to  produce  hybrido-
as. These  methods  have  a very  low  efﬁciency,  so
lternative  strategies  have  been  developed.  Such
lternatives  include  the  humanization  of  murine
onoclonal antibodies  through  protein  engineer-
ng, the  selection  of  human  antibodies  from  phage
isplay libraries  as  well  as  the  immunization  of
ransgenic  mice  carrying  human  immunoglobulin
oci combined  with  the  production  of  mono-
lonal antibodies  using  the  hybridoma  technology.
lthough these  methods  have  led  to  the  develop-
ent of  several  therapeutic  monoclonal  antibodies
gainst cytokines  or  surface  antigens,  their  impact
n infectious  disease  therapy  has  been  less  success-
ul. There  are  several  advantages  to  using  human
emory  B  cells  for  the  production  of  monoclonal
ntibodies: (i)  antibodies  are  fully  human,  (ii)  mem-
ry B  cells  are  readily  accessible  in  blood  and  persist
or a lifetime,  (iii)  there  is  low  or  no  risk  of  cross-
eactivity against  self-antigens,  (iv)  the  human
mmune  response  is  directed  against  the  virulent
athogen,  (v)  functional  assays  can  be  used  to  iso-
ate antibodies  based  on  their  function  (‘‘agnostic
pproach’’) with  no  need  to  use  molecular  targets
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Table  1  Examples  of  human  monoclonal  antibodies  isolated  using  the  Cellclone  Technology  developed  at  Humabs.
Target  Findings  Reference
SARS  Potent  and  broadly  neutralizing  antibodies  Nat.  Med.  2004;  J.  Virol.
2008
Diphtheria  toxin  Sub-stoichiometric  neutralization  of  the  toxin  Unpublished
Anthrax
protective
antigen
Sub-stoichiometric  neutralization  of  the  toxin  Unpublished
HIV-1 Neutralizing  antibodies  targeting  different  sites
including  heptad  repeat  1
PLoS ONE  2010;  PLoS
Pathogens  2010
Inﬂuenza  A  Broadly  neutralizing  and  pan-inﬂuenza  A
neutralizing  antibodies
J. Clin.  Invest.  2010;
Science  2011;  Nature
2014
HCMV  Extremely  potent  neutralizing  antibodies
targeting  the  gHgLpUL  pentameric  complex
J.  Virol.  2010;  PNAS  2014
RSV/MPV/PVM/BRSV  An  antibody  that  neutralizes  4  paramyxoviruses  Nature  2013
Plasmodium
falciparum
Antibodies  to  VAR2  CSA,  MSP2  and  p27.
Fc-dependent  killing  of  parasites.  Novel
antibodies  targeting  a  conserved  antigen  on
the  blood  stage  of  malaria
Mol. Microbiol.  2007;
Infect.  Immun.  2011;
Nature  2016
Norovirus  Analysis  of  the  GII.4  norovirus  evolution PLoS  Path.  2012;  J.  Virol.
2014
Dengue  Virus Fc-engineered  antibodies  neutralizing  all  4
serotypes  and  effective  in  an  ADE  mouse  model
Cell Host  Microbe  2010;
PLoS  Path.  2013
Rabies  Virus Potent  and  broadly  neutralizing  antibodies
covering  all  seven  lyssavirus  genotypes
EMBO  Mol.  Med.  2016
S.  aureus  Anti-MSCRAMMs  and  other  target  molecules
antibodies  with  therapeutic  potential
Unpublished
Avian  Flu  (H5N1)  Potent  and  broadly  neutralizing  antibodies  PLoS  Med.  2007;  PNAS
2015
Ebola  Potent  antibody  neutralizing  Ebola  virus  as
monotherapy  in  non-human  primates
Science  2016
HBV  Potent  neutralizing  antibodies  against  HBsAg
covering  all  genotypes  and  drug  selected
mutants
Manuscript  in
preparation
HCV  Potent  and  broadly  neutralizing  antibodies  Unpublished
MERS  Potent  and  broadly  neutralizing  antibody  PNAS  2015
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ws  baits  for  antibody  isolation,  and  (vi)  the  process
an be  very  fast.
In  2004,  the  Lanzavecchia’s  group  at  the  Insti-
ute for  Research  in  Biomedicine  (IRB)  in  Bellinzona
escribed an  improved  method  of  EBV  transfor-
ation of  human  B  cells  [7]. This  method,  called
ellclone Technology  (www.humabs.com),  was  fur-
her optimized  and  used  for  the  isolation  of
ntibodies against  a  large  set  of  viral  and  bacterial
athogens (Table  1)  [8].  Importantly,  antibodies  iso-
ated with  this  approach  are  being  tested  in  clinical
rials  through  a  partnership  with  pharmaceutical
ndustries.
The Cellclone  Technology  was  also  used  for  the
solation of  a  potent  monoclonal  antibody  that
as able  to  neutralize  a  MERS-CoV  infection  [9].
he second  patient  ever  reported  with  MERS,  a
h
D
t9-year-old  man  from  Qatar,  was  hospitalized  with
evere respiratory  failure  in  London.  Public  Health
ngland isolated  the  MERS  virus  from  this  patient
A/England/1/2012)  and  determined  the  presence
f neutralizing  antibodies  during  recovery  from  his
nitial illness,  which  was  suitable  for  the  Cell-
lone approach.  Memory  B  cells  were  obtained  from
his patient  eight  months  after  the  onset  of  the
ERS infection  in  May  2013  (when  neutralizing  anti-
odies were  still  detectable  in  peripheral  blood),
nd supernatants  from  single  antibody-producing
 cell  clones  were  tested  for  virus  neutralization
sing a  pseudotyped  neutralization  assay.  This  assay
as rapidly  developed  once  the  sequence  of  the
omologous  MERS-CoV  spike  protein  was  available.
espite  a  weak  neutralizing  serum  titer,  we  iden-
iﬁed one  B  cell  clone  among  the  4600  B cell
234  D.  Corti  et  al.
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(Figure  2  Rapid  isolation  of  MERS-CoV  human
clones  tested,  that  produced  a  monoclonal  antibody
(dubbed  LCA60)  with  potent  neutralizing  activity
against  the  MERS-CoV  pseudovirus.  A  stable  CHO
cell line  producing  the  neutralizing  LCA60  anti-
body was  established,  allowing  the  production  of
high yields  of  LCA60.  Of  note,  the  entire  project
took only  four  months  from  drawing  the  blood  sam-
ples to  establishing  the  stable  CHO  cell  line  that
produced  LCA60  (Fig.  2).  LCA60  was  efﬁciently  neu-
tralized  the  infectious  MERS-CoV  from  the  London
patient, as  well  as  additional  isolates  obtained  from
Saudi Arabia  and  Jordan  (IC50  values,  279  ng/mL
for England/1/2012,  150  ng/mL  for  EMC/2012,  and
110 ng/mL  for  the  Jordan-N3/2012  isolate).  Fur-
thermore,  LCA60  efﬁciently  neutralized  a  panel
of monoclonal  antibody-resistant  viral  mutants
(MARMs) that  were  previously  selected  using  phage-
derived  antibodies  that  were  mapped  to  3  different
regions in  the  receptor-binding  domain  (RBD)  of
the spike  protein.  LCA60  was  found  to  target  the
receptor-binding  domain  (RBD)  of  the  spike  protein
of the  virus.  The  spike  protein  mediates  binding
to CD26  (also  known  as  dipeptidyl  peptidase  4),
which serves  as  the  host  cell  receptor  of  MERS-CoV
and facilities  cell  entry  of  the  virus  by  membrane
fusion. LCA60  showed  subnanomolar  afﬁnity  for  the
spike protein  (KD 0.12  nM),  which  was  ∼500-fold
higher when  compared  to  that  of  the  human  recep-
tor CD26.
The  epitope  recognized  by  LCA60  was  identiﬁed
using a  combination  of  computational  predictions,
experimental validation  and  the  generation  of
escape  variants.  According  to  a  predicted  model,
the LCA60  footprint  on  the  RBD  was  shown  to
partially overlap  with  that  of  the  CD26  recep-
tor. This  model  was  conﬁrmed  by  the  results  of
cross-competition  experiments  showing  that  LCA60
prevented  the  binding  of  CD26  to  RBD,  thus
demonstrating  that  LCA60  neutralizes  the  MERS-
CoV infection  by  blocking  the  binding  to  its  cellular
receptor.The rapid  isolation  of  LCA60  was  also  par-
alleled by  the  rapid  development  of  an  animal
model for  MERS-CoV  based  on  transient  expressiontralizing  antibodies  from  a  survivor  in  2013.
f  the  human  CD26  receptor  in  wild-type  or
mmune-deﬁcient  mice.  In  this  model,  LCA60
howed high  efﬁcacy  both  in  prophylaxis  and
herapy by  reducing  lung  viral  titers  of  100—1000-
old, as  well  as  by  reducing  disease  signs  and
athology.
This research  has  demonstrated  several  ﬁndings
pplicable to  all  viral  emerging  diseases  for  which
o vaccines  or  medications  are  currently  avail-
ble, but  it  also  raises  important  considerations  for
uture research:
1) In  an  emergency,  the  isolation  of  memory  B cells
from  convalescent  patients  allows  the  swift
generation of  effective  therapeutic  antibodies
[10].
2) A  rapid  development  path  for  testing  new  ther-
apeutics  in  the  clinic  should  be  implemented  to
combat  emerging  virus  outbreaks.
3) It  is  important  that  regulatory  agencies  and
global public  health  authorities  continue  imple-
menting  and  supporting  adaptive  clinical  trials
design  aimed  at  testing  and  comparing  multiple
candidate drugs  during  outbreaks  [11].
4) LCA60  represents  a  promising  approach  for  both
prevention  and  therapy  of  MERS-CoV  infections.
The  LCA60  anti-MERS  monoclonal  antibody  in
brief
LCA60  is  the  only  antibody  isolated  from  a
recovered MERS  patient.  It  is  naturally  afﬁnity-
matured fully  human  IgG1  monoclonal  antibody
and potently  neutralizes  MERS-CoV  infection  of
multiple  isolates  in  vitro  and  in  vivo  by  preven-
ting the  interaction  of  the  viral  spike  protein
with its  cellular  receptor.  The  product  has
ﬁnished preclinical  development  and  a  GMP-
approved cell  line  expressing  the  puriﬁed  and
highly potent  antibody  in  high  concentrations  is
established.  The  non-proﬁt  development  path
will reduce  end-user  costs  considerably.
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